Biotech Firm Prepares Antiviral Drug Trials as Measles Cases Surge Globally

Shelton, Monday, 31 August 2026. With U.S. measles cases surpassing 2025 totals, NanoViricides is preparing Phase II clinical trials for NV-387, a broad-spectrum antiviral candidate showing strong efficacy against lethal infections.